363 related articles for article (PubMed ID: 19726410)
1. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease.
Nishioka K; Kefi M; Jasinska-Myga B; Wider C; Vilariño-Güell C; Ross OA; Heckman MG; Middleton LT; Ishihara-Paul L; Gibson RA; Amouri R; Ben Yahmed S; Ben Sassi S; Zouari M; El Euch G; Farrer MJ; Hentati F
J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):391-5. PubMed ID: 19726410
[TBL] [Abstract][Full Text] [Related]
2. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
3. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
[TBL] [Abstract][Full Text] [Related]
4. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
Tan MMX; Malek N; Lawton MA; Hubbard L; Pittman AM; Joseph T; Hehir J; Swallow DMA; Grosset KA; Marrinan SL; Bajaj N; Barker RA; Burn DJ; Bresner C; Foltynie T; Hardy J; Wood N; Ben-Shlomo Y; Grosset DG; Williams NM; Morris HR
Brain; 2019 Sep; 142(9):2828-2844. PubMed ID: 31324919
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2.
Bras J; Guerreiro R; Ribeiro M; Morgadinho A; Januario C; Dias M; Calado A; Semedo C; Oliveira C; Hardy J; Singleton A
BMC Neurol; 2008 Jan; 8():1. PubMed ID: 18211709
[TBL] [Abstract][Full Text] [Related]
7. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations.
Camargos ST; Dornas LO; Momeni P; Lees A; Hardy J; Singleton A; Cardoso F
Mov Disord; 2009 Apr; 24(5):662-6. PubMed ID: 19205068
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
11. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
12. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia.
Mellick GD; Siebert GA; Funayama M; Buchanan DD; Li Y; Imamichi Y; Yoshino H; Silburn PA; Hattori N
Parkinsonism Relat Disord; 2009 Feb; 15(2):105-9. PubMed ID: 18486522
[TBL] [Abstract][Full Text] [Related]
13. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease.
Kilarski LL; Pearson JP; Newsway V; Majounie E; Knipe MD; Misbahuddin A; Chinnery PF; Burn DJ; Clarke CE; Marion MH; Lewthwaite AJ; Nicholl DJ; Wood NW; Morrison KE; Williams-Gray CH; Evans JR; Sawcer SJ; Barker RA; Wickremaratchi MM; Ben-Shlomo Y; Williams NM; Morris HR
Mov Disord; 2012 Oct; 27(12):1522-9. PubMed ID: 22956510
[TBL] [Abstract][Full Text] [Related]
16. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
[TBL] [Abstract][Full Text] [Related]
18. Genetics of Parkinson's disease.
Bonifati V
Minerva Med; 2005 Jun; 96(3):175-86. PubMed ID: 16175160
[TBL] [Abstract][Full Text] [Related]
19. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease.
Macedo MG; Verbaan D; Fang Y; van Rooden SM; Visser M; Anar B; Uras A; Groen JL; Rizzu P; van Hilten JJ; Heutink P
Mov Disord; 2009 Jan; 24(2):196-203. PubMed ID: 18973254
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
